References
- Kone-Paut I, Piram M, Guillaume S, et al. Lupus in adolescence. Lupus. 2007;16:606–612.
- Levy DM, Massicotte MP, Harvey E, et al. Thromboembolism in paediatric lupus patients. Lupus. 2003;12:741–746.
- Campos LM, Kiss MH, D’Amico EA, et al. Antiphospholipid antibodies and antiphospholipid syndrome in 57 children and adolescents with systemic lupus erythematosus. Lupus. 2003;12:820–826.
- Uthman I, Khamashta M. The abdominal manifestations of the antiphospholipid syndrome. Rheumatology (Oxford). 2007;46:1641–1647.
- Tanaka M, Wanless IR. Pathology of the liver in Budd-Chiari syndrome: portal vein thrombosis and the histogenesis of veno-centric cirrhosis, veno-portal cirrhosis, and large regenerative nodules. Hepatology. 1998;27:488–496.
- Brancatelli G, Federle MP, Grazioli L, et al. Benign regenerative nodules in Budd-Chiari syndrome and other vascular disorders of the liver: radiologic-pathologic and clinical correlation. Radiographics. 2002;22:847–862.
- Ravelli A, Caria MC, Malattia C, et al. Uncommon causes of liver disease in juvenile systemic lupus erythematosus. Clin Exp Rheumatol. 2001;19:474.
- Menon KV, Shah V, Kamath PS. The Budd-Chiari syndrome. N Engl J Med. 2004;350:578–585.
- Pomeroy C, Knodell RG, Swain WR, et al. Budd-Chiari syndrome in a patient with the lupus anticoagulante. Gastroenterology. 1984;86:158–161.
- Aggarwal R, Ravishankar B, Misra R, et al. Significance of elevated IgG anticardiolipin antibody levels in patients with Budd-Chiari syndrome. Am J Gastroenterol. 1998;93:954–957.
- Winston CB, Schwartz LH, Fong Y, et al. Hepatocellular carcinoma: MR imaging findings in cirrhotic livers and noncirrhotic livers. Radiology. 1999;210:75–79.
- Moucari R, Rautou PE, Cazals-Hatem D, et al. Hepatocellular carcinoma in Budd-Chiari syndrome: characteristics and risk factors. Gut. 2008;57:828–835.
- International Working Party. Terminology of nodular hepatocellular lesions. Hepatology. 1995;22:983–993.
- Vilgrain V, Lewin M, Vons C, et al. Hepatic nodules in Budd-Chiari syndrome: imaging features. Radiology. 1999;210:443–450.
- Di Bisceglie AM, Carithers RL Jr, Gores GJ. Hepatocellular carcinoma. Hepatology. 1998;28:1161–1165.
- Cazals-Hatem D, Vilgrain V, Genin P, et al. Arterial and portal circulation and parenchymal changes in Budd-Chiari syndrome: a study in 17 explanted livers. Hepatology. 2003;37:510–519.
- Jiyad Z, Olsen CM, Burke MT, et al. Azathioprine and risk of skin cancer in organ transplant recipients: systematic review and meta-analysis. Am J Transplant. 2016;16:3490–3503.
- Beaugerie L, Brousse N, Bouvier AM, et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet. 2009;374:1617–1625.
- O’Donovan P, Perrett CM, Zhang X, et al. Azathioprine and UVA light generate mutagenic oxidative DNA damage. Science. 2005;309:1871–1874.
- Cuffari C, Li DY, Mahoney J, et al. Peripheral blood mononuclear cell DNA 6-thioguanine metabolite levels correlate with decreased interferon-gamma production in patients with Crohn’s disease on AZA therapy. Dig Dis Sci. 2004;49:133–137.
- Uribe-Luna S, Quintana-Hau JD, Maldonado-Rodriguez R, et al. Mutagenic consequences of the incorporation of 6-thioguanine into DNA. Biochem Pharmacol. 1997;54:419–424.
- Armstrong RG, West J, Card TR. Risk of cancer in inflammatory bowel disease treated with azathioprine: a UK population-based case-control study. Am J Gastroenterol. 2010;105:1604–1609.
- Pasternak B, Svanstrom H, Schmiegelow K, et al. Use of azathioprine and the risk of cancer in inflammatory bowel disease. Am J Epidemiol. 2013;177:1296–1305.
- Ishida M, Naka S, Shiomi H, et al. Hepatocellular carcinoma occurring in a Crohn’s disease patient. World J Gastroenterol. 2010;16:3215–3218.
- Samarasena J, Borgaonkar M. Development of hepatocellular carcinoma in a patient with Crohn’s disease treated with azathioprine. Dig Dis Sci. 2007;52:2748–2750.
- Borum ML. Unusual development of hepatocellular carcinoma in a patient with Crohn’s disease. Dig Dis Sci. 2001;46:2199–2200.